Skip to main content

Cannabinoids: Do they have a Role in Cancer Therapy?

Buy Article:

$68.00 + tax (Refund Policy)

Cannabinoids, the active components of the cannabis plant, have merit as an anti-emetic and appetite stimulant in people with cancer. Recently, interest in cannabinoids has increased since reports that cannabinoids have anti-tumour activity. Although the mechanisms underlying these effects have yet to be fully elucidated, a broad spectrum of effects have been described, and cellular signalling pathways are known to be involved. There are currently two major cannabinoid receptors identified, whose roles in the activation of cell death remains controversial. Agonists to the type-2 receptor that do not have psychotropic effects have been used successfully in vitro, and we await the results of randomised trials using theses agents. The field of research into cannabinoids as anti-cancer agents is in its infancy, and more basic research is required before a good clinical agent can be realised. This article reviews the data currently available on this exciting group of potential anti-neoplastic agent.

Keywords: CB1-receptor; cyclo-oxygenase 2; neuromodulation; phosphodiesterases; signal transduction pathways

Document Type: Research Article

Affiliations: Section of Medicine, Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, SM2 5NG, UK.

Publication date: March 1, 2006

More about this publication?
  • Letters in Drug Design & Discovery publishes original letters on all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts. The journal is essential reading to all pharmaceutical scientists involved in research in drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content